Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Tongjitang Chinese Medicines Makes Another Small Acquisition

publication date: Apr 3, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Tongjitang Chinese Medicines Company (同济堂药业) will acquire Anhui Jingfang Pharmaceutical Co. Ltd., a privately owned company, for 60 million RMB ($8.8 million). Like Tongjitang, Jingfang is a TCM drug company with products in the orthopedics and geriatrics markets. Jingfang's product portfolio includes more than thirty Western and traditional Chinese medicines. The company is profitable, producing revenue of 56 million RMB in 2007, which fell to 41 million RMB in 2008. More details...

Stock Symbol: (NYSE: TCM)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors